# The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies

> **NCT06552598** · PHASE1 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 97 (estimated)

## Conditions studied

- Cervical Cancer
- Gynecologic Malignancies
- Endometrial Cancer

## Interventions

- **DRUG:** KD01(the recombinant oncolytic adenovirus)

## Key facts

- **NCT ID:** NCT06552598
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 97 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06552598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06552598, "The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06552598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*